metformin and Adenocarcinoma, Basal Cell studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

Excerpt	Relevance	Reference
"An open label, three-armed, randomised, phase-II, multi-centre trial of LNG-IUD ± metformin ± weight loss intervention."	9.19	Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. ( Armes, J; Brennan, D; Gebski, V; Hawkes, AL; Janda, M; Obermair, A; Quinn, M, 2014)
"Metformin may improve the prognosis in gastric adenocarcinoma, but the existing literature is limited and contradictory."	8.02	Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study. ( Lagergren, J; Santoni, G; Xie, SH; Zheng, J, 2021)
"Whether or not the use of metformin decreases the risk of gastric adenocarcinoma is unclear."	7.91	Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. ( Lagergren, J; Santoni, G; Xie, SH; Zheng, J, 2019)
"In the first population based study of metformin use in gastric cancer adenocarcinoma patients with previous diabetes, our findings suggest that metformin use might improve overall mortality."	7.88	Impact of metformin on gastric adenocarcinoma survival: A Belgian population based study. ( Cardwell, CR; Couttenier, A; De Schutter, H; Lacroix, O; Robert, A; Vaes, E, 2018)
" Importantly, metformin inhibited tumor growth and distant metastases in tumor-bearing nude mice and reversed IL-6-induced EMT both in vitro and in vivo."	7.80	Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. ( Cheng, X; Han, R; He, L; He, Y; Li, L; Long, H; Wang, Y; Xiang, T; Zhao, Z; Zhu, B, 2014)
"Two hundred eighty-five patients with esophageal adenocarcinoma treated with concurrent chemoradiation (CRT) followed by esophagectomy from 1997 to 2012 were included in the study, including 29 diabetics taking metformin, 21 diabetics not taking metformin and 235 non-diabetics."	7.79	Metformin use and improved response to therapy in esophageal adenocarcinoma. ( Ajani, JA; Cox, JD; Echeverria, AE; Guerrero, TM; Hofstetter, WL; Komaki, R; Lin, SH; McCurdy, MR; Myers, JN; O'Reilly, MS; Sandulache, VC; Skinner, HD; Welsh, JW, 2013)
" In the present study, the combined effects of metformin and gefitinib were examined in vivo in a mouse xenograft model, inoculated with a human lung adenocarcinoma cell line that possesses an activating epidermal growth factor receptor mutation."	7.79	Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. ( Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O, 2013)
"To stimulate EC carcinogenesis, chronic gastroduodenal reflux esophagitis via esophagojejunostomy was induced in 120 rats in metformin-treated and non-treated (control) groups."	5.72	Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis. ( Fushida, S; Harashima, A; Inaki, N; Miyashita, T; Munesue, S; Ninomiya, I; Ohta, T; Tajima, H; Takada, S; Takamura, H; Takei, R; Yagi, S; Yamamoto, Y, 2022)
"High mortality rates in ovarian and liver cancer are largely a result of resistance to currently used chemotherapy."	5.48	Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. ( Bukowska, B; Marczak, A; Rogalska, A, 2018)
"Treatment with metformin of athymic nude mice bearing xenograft tumors reduced tumor proliferation."	5.42	Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. ( Chiyo, T; Fujihara, S; Iwama, H; Kato, K; Kobara, H; Kobayashi, M; Masaki, T; Miyoshi, H; Mori, H; Morishita, A; Nishioka, T; Nishiyama, N; Okano, K; Suzuki, Y, 2015)
"Metformin use was neither associated with an increased nor a decreased risk of esophageal cancer."	5.40	Metformin use and the risk of esophageal cancer in Barrett esophagus. ( Agrawal, A; Agrawal, S; Deidrich, W; Makhijani, N; Markert, R; Patel, P, 2014)
"Metformin is a synthetic biguanide that improves insulin sensitivity and reduces hepatic gluconeogenesis."	5.22	Metformin in Differentiated Thyroid Cancer: Molecular Pathways and Its Clinical Implications. ( Ferreira-Hermosillo, A; García-Sáenz, M; Lobaton-Ginsberg, M, 2022)
"An open label, three-armed, randomised, phase-II, multi-centre trial of LNG-IUD ± metformin ± weight loss intervention."	5.19	Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. ( Armes, J; Brennan, D; Gebski, V; Hawkes, AL; Janda, M; Obermair, A; Quinn, M, 2014)
"Metformin may improve the prognosis in gastric adenocarcinoma, but the existing literature is limited and contradictory."	4.02	Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study. ( Lagergren, J; Santoni, G; Xie, SH; Zheng, J, 2021)
"Whether or not the use of metformin decreases the risk of gastric adenocarcinoma is unclear."	3.91	Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. ( Lagergren, J; Santoni, G; Xie, SH; Zheng, J, 2019)
"In the first population based study of metformin use in gastric cancer adenocarcinoma patients with previous diabetes, our findings suggest that metformin use might improve overall mortality."	3.88	Impact of metformin on gastric adenocarcinoma survival: A Belgian population based study. ( Cardwell, CR; Couttenier, A; De Schutter, H; Lacroix, O; Robert, A; Vaes, E, 2018)
" Here, we show that treatment of pancreatic ductal adenocarcinoma (PDAC) cells (PANC-1, MiaPaCa-2) with the isoquinoline alkaloid berberine (0."	3.80	Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. ( Eibl, G; Ming, M; Rozengurt, E; Sinnett-Smith, J; Soares, HP; Wang, J; Young, SH, 2014)
" Importantly, metformin inhibited tumor growth and distant metastases in tumor-bearing nude mice and reversed IL-6-induced EMT both in vitro and in vivo."	3.80	Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. ( Cheng, X; Han, R; He, L; He, Y; Li, L; Long, H; Wang, Y; Xiang, T; Zhao, Z; Zhu, B, 2014)
"Our clinical study indicates esophageal adenocarcinoma patients on metformin had a better treatment response than those without metformin."	3.80	Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. ( Ajani, JA; Chen, Q; Honjo, S; Johnson, RL; Scott, AW; Skinner, HD; Song, S; Stroehlein, J, 2014)
" In the present study, the combined effects of metformin and gefitinib were examined in vivo in a mouse xenograft model, inoculated with a human lung adenocarcinoma cell line that possesses an activating epidermal growth factor receptor mutation."	3.79	Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. ( Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O, 2013)
"Two hundred eighty-five patients with esophageal adenocarcinoma treated with concurrent chemoradiation (CRT) followed by esophagectomy from 1997 to 2012 were included in the study, including 29 diabetics taking metformin, 21 diabetics not taking metformin and 235 non-diabetics."	3.79	Metformin use and improved response to therapy in esophageal adenocarcinoma. ( Ajani, JA; Cox, JD; Echeverria, AE; Guerrero, TM; Hofstetter, WL; Komaki, R; Lin, SH; McCurdy, MR; Myers, JN; O'Reilly, MS; Sandulache, VC; Skinner, HD; Welsh, JW, 2013)
" We found that in LKB1-null A549 lung adenocarcinoma cells, an AMPK activator, metformin, failed to block the nuclear export of PTEN, and the reintroduction of functional LKB1 into these cells restored the metformin-mediated inhibition of the nuclear export of PTEN."	3.77	AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. ( Gallick, GE; Liu, JL; Mao, Z; Yung, WK, 2011)
" The patient also had type 2 diabetes mellitus; metformin therapy had been initiated 5 years before presentation."	3.75	Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. ( Fimognari, FL; Franco, A; Pastorelli, R; Pellegrinotti, M; Repetto, L, 2009)
"Metformin has been reported to be associated with improved cancer prognosis when used in combination with chemotherapy and/or radiotherapy."	2.82	Association of Tumor Pathological Response with the Use of Metformin During Neoadjuvant Chemoradiotherapy in Rectal and Esophageal/Gastroesophageal Cancer Patients: a Systematic Review and Meta-analysis. ( Kitagawa, Y; Matsui, S; Okabayashi, K; Sakamoto, K; Seishima, R; Shigeta, K, 2022)
"Treatment with metformin is safe in nondiabetic patients, and it yields objective PSA responses and may induce disease stabilization."	2.79	Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). ( Bärtschi, D; Cathomas, R; Endt, K; Gillessen, S; Hayoz, S; Lui, L; Pollak, M; Rothermundt, C; Rüschoff, JH; Schiess, R; Strebel, RT; Templeton, AJ; Winterhalder, R, 2014)
"Candidates for chemoprevention in Barrett's esophagus have long been suggested and there has been observational data to support many drugs, including statins, hormone replacement therapy, metformin, proton pump inhibitor therapy, and aspirin."	2.72	Current Status of Chemoprevention in Barrett's Esophagus. ( El-Serag, HB; Moayyedi, P, 2021)
"We identified 44 pancreatic cancer patients with diabetes who underwent resection of the primary tumor (19 with ongoing metformin use, 25 never used metformin)."	2.53	Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. ( Ambe, CM; Chen, L; Fulp, J; Mahipal, A; Malafa, MP, 2016)
"Chemoprevention in Barrett's esophagus is currently applied only in research settings."	2.52	Chemoprevention in Barrett's Esophagus: Current Status. ( Baruah, A; Buttar, NS; Kossak, SK; Zeb, MH, 2015)
"Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined."	2.50	Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014)
"To stimulate EC carcinogenesis, chronic gastroduodenal reflux esophagitis via esophagojejunostomy was induced in 120 rats in metformin-treated and non-treated (control) groups."	1.72	Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis. ( Fushida, S; Harashima, A; Inaki, N; Miyashita, T; Munesue, S; Ninomiya, I; Ohta, T; Tajima, H; Takada, S; Takamura, H; Takei, R; Yagi, S; Yamamoto, Y, 2022)
"The association of oesophageal cancer with drug use and clinical factors was evaluated."	1.72	Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study. ( Arai, J; Arai, M; Hasatani, K; Hayakawa, Y; Honda, T; Ikeya, T; Kawahara, T; Kawai, T; Kiyotoki, S; Koike, K; Niikura, R; Nishida, T; Sumiyoshi, T; Suzuki, N; Tsuji, Y; Yamada, A; Yoshida, N, 2022)
"The prognosis of pancreatic cancer is poor and new treatment strategies are urgently needed."	1.62	Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. ( Andreassen, BK; Botteri, E; Bouche, G; Pantziarka, P; Sloan, EK; Støer, NC, 2021)
"KRas is frequently mutated in pancreatic cancers."	1.62	GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021)
" Tissue and breath concentrations of the medium-chain alkanal decanal are correlated, and increased decanal is linked to reduced ALDH3A2 expression, TP53 deletion, and adverse clinical features."	1.62	Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. ( Adam, ME; Antonowicz, S; Bodai, Z; Boshier, PR; Fitzgerald, RC; Gabra, H; Goh, YM; Goldin, R; Green, CM; Habib, N; Hanna, GB; Kudo, H; Lu, H; Markar, SR; Moralli, D; Peters, CJ; Rosini, F; Takats, Z; Wiggins, T, 2021)
" Chronic use of other common drugs, namely, statins nonsteroidal anti-inflammatory drugs (NSAIDs) and metformin, may also interfere with BE carcinogenesis, but confirmatory evidence is lacking."	1.62	Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis. ( Chaloux, M; Loomans-Kropp, HA; Richmond, E; Umar, A, 2021)
"Treatment with metformin did not result in any apparent improvement in time to BF, time to metastasis detection or OS, but there was a 1."	1.51	Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. ( Baldwin, G; Bolton, D; Ischia, J; Patel, O; Ranasinghe, WKB; Sengupta, S; Shulkes, A; Wetherell, D; Williams, S, 2019)
" However, long term use of high dose progestin often lead to progestin resistance."	1.51	Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression. ( Chen, X; Feng, Y; Jiang, Y; Wei, Y; Zhang, Z; Zheng, W, 2019)
"High mortality rates in ovarian and liver cancer are largely a result of resistance to currently used chemotherapy."	1.48	Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. ( Bukowska, B; Marczak, A; Rogalska, A, 2018)
"BE subjects developing esophageal cancer (EC) 12 months after their index BE diagnosis were defined as progressors."	1.43	Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. ( Borah, B; Chak, A; Das, A; Heien, H; Iyer, PG; Krishnamoorthi, R, 2016)
"Metformin is an anti-diabetic drug with anticancer activity by inhibiting tumor cell proliferation."	1.43	Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis. ( Eo, SK; Lee, JH; Lee, YJ; Moon, JH; Nazim, UM; Park, SY; Seol, JW, 2016)
"Treatment with metformin of athymic nude mice bearing xenograft tumors reduced tumor proliferation."	1.42	Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. ( Chiyo, T; Fujihara, S; Iwama, H; Kato, K; Kobara, H; Kobayashi, M; Masaki, T; Miyoshi, H; Mori, H; Morishita, A; Nishioka, T; Nishiyama, N; Okano, K; Suzuki, Y, 2015)
"Inhibition of prostate cancer progression in HiMyc mice by RAPA was associated with a significant reduction in mTORC1 signaling that was further potentiated by the combination of MET and RAPA."	1.42	Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice. ( Blando, J; DiGiovanni, J; Saha, A; Tremmel, L, 2015)
"Metformin use has been associated with a dose-dependent increased response to neoadjuvant chemo(radio)therapy in esophageal cancer patients."	1.42	Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. ( Anderegg, MC; Gisbertz, SS; Hulshof, MC; Lagarde, SM; Meijer, SL; Spierings, LE; van Berge Henegouwen, MI; van Laarhoven, HW; van Oijen, MG; Wilmink, JW, 2015)
"Metformin is a widely used glucose-lowering drug."	1.42	Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. ( Babykutty, S; Chen, I; Chin, SM; Deshpande, V; Fukumura, D; Hato, T; Incio, J; Jain, RK; Liu, H; Suboj, P; Vardam-Kaur, T, 2015)
"Metformin use was neither associated with an increased nor a decreased risk of esophageal cancer."	1.40	Metformin use and the risk of esophageal cancer in Barrett esophagus. ( Agrawal, A; Agrawal, S; Deidrich, W; Makhijani, N; Markert, R; Patel, P, 2014)
"Locally advanced rectal cancer is commonly treated with chemoradiation prior to total mesorectal excision (TME)."	1.39	Metformin use and improved response to therapy in rectal cancer. ( Chang, GJ; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kelly, P; Krishnan, S; Rodriguez-Bigas, MA; Sandulache, VC; Skibber, JM; Skinner, HD, 2013)
"The treatment metformin alone inhibited the growth of transplantable HER2 mammary carcinoma in FVB/N male mice by 46% at the 45(th) day after transplantation (p < 0."	1.36	Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. ( Anikin, IV; Anisimov, VN; Egormin, PA; Karkach, AS; Piskunova, TS; Popovich, IG; Romanyukha, AA; Tyndyk, ML; Yurova, MN; Zabezhinski, MA, 2010)
"Metformin use was associated with reduced risk, and insulin or insulin secretagogue use was associated with increased risk of pancreatic cancer in diabetic patients."	1.35	Antidiabetic therapies affect risk of pancreatic cancer. ( Abbruzzese, JL; Hassan, MM; Konopleva, M; Li, D; Yeung, SC, 2009)
"The human pancreatic cancer cell lines ASPC-1, BxPc-3, PANC-1 and SW1990 were exposed to metformin."	1.35	Metformin induces apoptosis of pancreatic cancer cells. ( Gao, J; Jin, ZD; Li, ZS; Wang, LW; Xu, GM; Zou, DW, 2008)

Research

Studies (63)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Concentration of Metformin in Adipose Tissue

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (7.94)	29.6817
2010's	44 (69.84)	24.3611
2020's	14 (22.22)	2.80

Authors	Studies
Arai, J	1
Niikura, R	1
Hayakawa, Y	1
Kawahara, T	1
Honda, T	1
Hasatani, K	1
Yoshida, N	1
Nishida, T	1
Sumiyoshi, T	1
Kiyotoki, S	1
Ikeya, T	1
Arai, M	1
Suzuki, N	1
Tsuji, Y	1
Yamada, A	1
Kawai, T	1
Koike, K	1
García-Sáenz, M	1
Lobaton-Ginsberg, M	1
Ferreira-Hermosillo, A	1
Qiu, C	1
Li, C	1
Zheng, Q	1
Fang, S	1
Xu, J	1
Wang, H	1
Guo, H	1
Sakamoto, K	1
Okabayashi, K	1
Matsui, S	1
Seishima, R	1
Shigeta, K	1
Kitagawa, Y	1
Pretta, A	2
Ziranu, P	2
Giampieri, R	2
Donisi, C	2
Cimbro, E	2
Spanu, D	2
Lai, E	2
Pecci, F	2
Balconi, F	2
Lupi, A	2
Pozzari, M	2
Persano, M	2
Murgia, S	2
Pusceddu, V	2
Puzzoni, M	2
Berardi, R	2
Scartozzi, M	2
Vedire, YR	1
Mukherjee, S	1
Dondapati, S	1
Yendamuri, S	1
Stirrups, R	1
Zheng, J	2
Xie, SH	2
Santoni, G	2
Lagergren, J	2
Han, H	1
Hou, Y	1
Chen, X	2
Zhang, P	1
Kang, M	1
Jin, Q	1
Ji, J	1
Gao, M	1
Loomans-Kropp, HA	1
Chaloux, M	1
Richmond, E	1
Umar, A	1
Moayyedi, P	1
El-Serag, HB	1
Antonowicz, S	1
Bodai, Z	1
Wiggins, T	1
Markar, SR	1
Boshier, PR	1
Goh, YM	1
Adam, ME	1
Lu, H	1
Kudo, H	1
Rosini, F	1
Goldin, R	1
Moralli, D	1
Green, CM	1
Peters, CJ	1
Habib, N	1
Gabra, H	1
Fitzgerald, RC	1
Takats, Z	1
Hanna, GB	1
Abrams, SL	1
Akula, SM	1
Meher, AK	1
Steelman, LS	1
Gizak, A	1
Duda, P	1
Rakus, D	1
Martelli, AM	1
Ratti, S	1
Cocco, L	1
Montalto, G	1
Cervello, M	1
Ruvolo, P	1
Libra, M	1
Falzone, L	1
Candido, S	1
McCubrey, JA	1
Støer, NC	1
Bouche, G	1
Pantziarka, P	1
Sloan, EK	1
Andreassen, BK	1
Botteri, E	1
Takei, R	1
Miyashita, T	1
Takada, S	1
Tajima, H	1
Ninomiya, I	1
Takamura, H	1
Fushida, S	1
Harashima, A	1
Munesue, S	1
Yagi, S	1
Inaki, N	1
Ohta, T	1
Yamamoto, Y	1
Chiyo, T	2
Kato, K	2
Iwama, H	2
Fujihara, S	2
Fujita, K	1
Tadokoro, T	1
Ohura, K	1
Samukawa, E	1
Yamana, Y	1
Kobayashi, N	1
Matsunaga, T	1
Nishiyama, N	2
Ayaki, M	1
Yachida, T	1
Morishita, A	2
Kobara, H	2
Mori, H	2
Masaki, T	2
E, JY	1
Lu, SE	1
Lin, Y	1
Graber, JM	1
Rotter, D	1
Zhang, L	1
Petersen, GM	2
Demissie, K	1
Lu-Yao, G	1
Tan, XL	1
Rogalska, A	1
Bukowska, B	1
Marczak, A	1
Zhou, C	1
Sun, H	1
Zheng, C	1
Gao, J	2
Fu, Q	1
Hu, N	1
Shao, X	1
Zhou, Y	1
Xiong, J	1
Nie, K	1
Zhou, H	1
Shen, L	1
Fang, H	1
Lyu, J	1
Lacroix, O	1
Couttenier, A	1
Vaes, E	1
Cardwell, CR	1
De Schutter, H	1
Robert, A	1
Jiang, Y	1
Wei, Y	1
Feng, Y	1
Zheng, W	1
Zhang, Z	1
Ranasinghe, WKB	1
Williams, S	1
Ischia, J	1
Wetherell, D	1
Baldwin, G	1
Shulkes, A	1
Sengupta, S	1
Bolton, D	1
Patel, O	1
Li, Y	1
Luo, J	1
Lin, MT	1
Zhi, P	1
Guo, WW	1
Han, M	1
You, J	1
Gao, JQ	1
El-Jurdi, NH	1
Saif, MW	2
Kitazono, S	1
Takiguchi, Y	2
Ashinuma, H	1
Saito-Kitazono, M	1
Kitamura, A	1
Chiba, T	1
Sakaida, E	1
Sekine, I	2
Tada, Y	2
Kurosu, K	1
Sakao, S	1
Tanabe, N	1
Iwama, A	2
Yokosuka, O	1
Tatsumi, K	2
Skinner, HD	3
Crane, CH	1
Garrett, CR	1
Eng, C	1
Chang, GJ	1
Skibber, JM	1
Rodriguez-Bigas, MA	1
Kelly, P	1
Sandulache, VC	2
Delclos, ME	1
Krishnan, S	1
Das, P	1
Rothermundt, C	1
Hayoz, S	1
Templeton, AJ	1
Winterhalder, R	1
Strebel, RT	1
Bärtschi, D	1
Pollak, M	1
Lui, L	1
Endt, K	1
Schiess, R	1
Rüschoff, JH	1
Cathomas, R	1
Gillessen, S	1
Hamilton, RJ	1
Zhao, Z	1
Cheng, X	1
Wang, Y	1
Han, R	1
Li, L	1
Xiang, T	1
He, L	1
Long, H	1
Zhu, B	1
He, Y	1
Honjo, S	1
Ajani, JA	2
Scott, AW	1
Chen, Q	1
Stroehlein, J	1
Johnson, RL	1
Song, S	1
Hawkes, AL	1
Quinn, M	1
Gebski, V	1
Armes, J	1
Brennan, D	1
Janda, M	1
Obermair, A	1
Burney, S	1
Khawaja, KI	1
Masud, F	1
Herrigel, DJ	1
Moss, RA	1
Ming, M	1
Sinnett-Smith, J	2
Wang, J	1
Soares, HP	1
Young, SH	1
Eibl, G	1
Rozengurt, E	2
Agrawal, S	1
Patel, P	1
Agrawal, A	1
Makhijani, N	1
Markert, R	1
Deidrich, W	1
Nishioka, T	1
Miyoshi, H	1
Kobayashi, M	1
Okano, K	1
Suzuki, Y	1
Saha, A	1
Blando, J	1
Tremmel, L	1
DiGiovanni, J	1
Zeb, MH	1
Baruah, A	1
Kossak, SK	1
Buttar, NS	1
Van De Voorde, L	1
Janssen, L	1
Larue, R	1
Houben, R	1
Buijsen, J	1
Sosef, M	1
Vanneste, B	1
Schraepen, MC	1
Berbée, M	1
Lambin, P	1
Spierings, LE	1
Lagarde, SM	1
van Oijen, MG	1
Gisbertz, SS	1
Wilmink, JW	1
Hulshof, MC	1
Meijer, SL	1
Anderegg, MC	1
van Berge Henegouwen, MI	1
van Laarhoven, HW	1
Chao, DT	1
Shah, NH	1
Zeh, HJ	1
Bahary, N	1
Whitcomb, DC	1
Brand, RE	1
Kim, J	1
Lee, J	1
Kim, C	1
Choi, J	1
Kim, A	1
Incio, J	1
Suboj, P	1
Chin, SM	1
Vardam-Kaur, T	1
Liu, H	1
Hato, T	1
Babykutty, S	1
Chen, I	1
Deshpande, V	1
Jain, RK	1
Fukumura, D	1
Zhou, G	1
Yu, J	1
Wang, A	1
Liu, SH	1
Wu, J	1
Sanchez, R	1
Nemunaitis, J	1
Ricordi, C	1
Brunicardi, FC	1
Krishnamoorthi, R	1
Borah, B	1
Heien, H	1
Das, A	1
Chak, A	1
Iyer, PG	1
Liu, Z	1
Qi, S	1
Zhao, X	1
Li, M	1
Ding, S	1
Lu, J	1
Zhang, H	1
Ambe, CM	1
Mahipal, A	1
Fulp, J	1
Chen, L	1
Malafa, MP	1
Kurimoto, R	1
Iwasawa, S	1
Ebata, T	1
Ishiwata, T	1
Koide, S	1
Nazim, UM	1
Moon, JH	1
Lee, JH	2
Lee, YJ	1
Seol, JW	1
Eo, SK	1
Park, SY	1
Chaiteerakij, R	1
Bamlet, WR	1
Chaffee, KG	1
Zhen, DB	1
Burch, PA	1
Leof, ER	1
Roberts, LR	1
Oberg, AL	1
Zechner, D	1
Bürtin, F	1
Albert, AC	1
Zhang, X	1
Kumstel, S	1
Schönrogge, M	1
Graffunder, J	1
Shih, HY	1
Müller, S	1
Radecke, T	1
Jaster, R	1
Vollmar, B	1
Wang, LW	1
Li, ZS	1
Zou, DW	1
Jin, ZD	1
Xu, GM	1
Pellegrinotti, M	1
Fimognari, FL	1
Franco, A	1
Repetto, L	1
Pastorelli, R	1
Li, D	1
Yeung, SC	1
Hassan, MM	1
Konopleva, M	1
Abbruzzese, JL	1
Anisimov, VN	2
Egormin, PA	2
Piskunova, TS	2
Popovich, IG	2
Tyndyk, ML	1
Yurova, MN	1
Zabezhinski, MA	1
Anikin, IV	1
Karkach, AS	1
Romanyukha, AA	1
Liu, JL	1
Mao, Z	1
Gallick, GE	1
Yung, WK	1
Wu, N	1
Gu, C	1
Gu, H	1
Hu, H	1
Han, Y	1
Li, Q	1
Wu, B	1
Li, S	1
Sheng, L	1
Zhu, J	1
Gu, L	1
Shen, H	1
La, D	1
Hambly, BD	1
Bao, S	1
Di, W	1
Flaherty, AM	1
McCurdy, MR	1
Echeverria, AE	1
Lin, SH	1
Welsh, JW	1
O'Reilly, MS	1
Hofstetter, WL	1
Komaki, R	1
Cox, JD	1
Myers, JN	1
Guerrero, TM	1
Bershtein, LM	1
Zabezhinskii, MA	1
Semenchenko, AV	1
Schneider, MB	1
Matsuzaki, H	1
Haorah, J	1
Ulrich, A	1
Standop, J	1
Ding, XZ	1
Adrian, TE	1
Pour, PM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome[NCT05600608]		100 participants (Anticipated)	Interventional	2022-11-30	Not yet recruiting
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547]	Phase 2	20 participants (Anticipated)	Interventional	2019-01-31	Not yet recruiting
Metformin in Castration Resistant Prostate Cancer. A Multicenter Phase II Trial.[NCT01243385]	Phase 2	44 participants (Actual)	Interventional	2010-12-23	Completed
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821]	Phase 3	168 participants (Actual)	Interventional	2018-07-12	Terminated (stopped due to Manufacturer discontinued the production of study drugs.)
Mansmed Trial : Repurposing Metformin as Anticancer Drug, RCT in Advanced Prostate Cancer[NCT03137186]	Phase 2	120 participants (Anticipated)	Interventional	2017-01-31	Recruiting
Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024]	Phase 2	50 participants (Anticipated)	Interventional	2015-03-31	Active, not recruiting
Metformin Pharmacology in Human Cancers[NCT03477162]	Early Phase 1	18 participants (Actual)	Interventional	2018-05-15	Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.)
Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367]	Phase 2	208 participants (Actual)	Interventional	2012-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Concentration of Metformin in Plasma.

Intervention	ng/g (Median)
Metformin	70

To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery

Concentration of Metformin in Tumor-adjacent Normal Tissue

Intervention	ng/mL (Median)
Metformin	450

To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Concentration of Metformin in Whole Blood.

Intervention	ng/g (Median)
Metformin	749

To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery

Lung Tumor Tissue Concentration of Metformin

Intervention	ng/mL (Median)
Metformin	514

To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery

Article	Year
Metformin in Differentiated Thyroid Cancer: Molecular Pathways and Its Clinical Implications. Biomolecules, 2022, 04-14, Volume: 12, Issue:4 Topics: Adenocarcinoma; Cell Cycle; Cell Proliferation; Diabetes Mellitus, Type 2; Humans; Insulin Resistanc	2022
Association of Tumor Pathological Response with the Use of Metformin During Neoadjuvant Chemoradiotherapy in Rectal and Esophageal/Gastroesophageal Cancer Patients: a Systematic Review and Meta-analysis. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2022, Volume: 26, Issue:10 Topics: Adenocarcinoma; Chemoradiotherapy; Esophageal Neoplasms; Humans; Metformin; Neoadjuvant Therapy; Rec	2022
Current Status of Chemoprevention in Barrett's Esophagus. Gastrointestinal endoscopy clinics of North America, 2021, Volume: 31, Issue:1 Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Chemoprevention; Drug Therapy, Combination; Esophageal N	2021
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. Postgraduate medicine, 2014, Volume: 126, Issue:6 Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp	2014
Chemoprevention in Barrett's Esophagus: Current Status. Gastroenterology clinics of North America, 2015, Volume: 44, Issue:2 Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Bile Acids and Salts; Cy	2015
Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. PloS one, 2016, Volume: 11, Issue:3 Topics: Adenocarcinoma; Humans; Kaplan-Meier Estimate; Metformin; Pancreatic Neoplasms	2016
Management of diabetes and pancreatic cancer. Oncology nursing forum, 2012, Volume: 39, Issue:5 Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera	2012

Article	Year
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple	2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple	2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple	2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple	2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple	2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple	2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple	2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple	2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple	2014
Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. Contemporary clinical trials, 2014, Volume: 39, Issue:1 Topics: Adenocarcinoma; Biomarkers, Tumor; Diet; Endometrial Neoplasms; Exercise; Female; Humans; Intrauteri	2014

Article	Year
Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study. Digestion, 2022, Volume: 103, Issue:3 Topics: Adenocarcinoma; Aspirin; Case-Control Studies; Chemoprevention; Esophageal Neoplasms; Esophageal Squ	2022
Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163. Bioengineered, 2022, Volume: 13, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung; Lung Neo	2022
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct	2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct	2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct	2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct	2023
Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer. Scientific reports, 2023, 05-24, Volume: 13, Issue:1 Topics: Adenocarcinoma; Colorectal Neoplasms; Female; Humans; Intra-Abdominal Fat; Male; Metformin; Obesity,	2023
Metformin plus EGFR TKIs for lung adenocarcinoma. The Lancet. Oncology, 2019, Volume: 20, Issue:10 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic;	2019
Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. British journal of cancer, 2019, Volume: 121, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Fe	2019
Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy. Journal of the American Chemical Society, 2020, 03-11, Volume: 142, Issue:10 Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; C	2020
Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis. Cancer prevention research (Philadelphia, Pa.), 2021, Volume: 14, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus;	2021
Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. Nature communications, 2021, 03-05, Volume: 12, Issue:1 Topics: Adenocarcinoma; Aldehyde Dehydrogenase; Aldehyde Oxidoreductases; Aldehydes; Biomarkers, Tumor; DNA	2021
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells, 2021, 04-06, Volume: 10, Issue:4 Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound	2021
Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study. British journal of cancer, 2021, Volume: 125, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Cause of Death; Cohort Studies; Female; Humans; Male; Metfo	2021
Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. Acta oncologica (Stockholm, Sweden), 2021, Volume: 60, Issue:9 Topics: Adenocarcinoma; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; P	2021
Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis. Cancer immunology, immunotherapy : CII, 2022, Volume: 71, Issue:4 Topics: Adenocarcinoma; Animals; Barrett Esophagus; Carcinogenesis; Esophageal Neoplasms; Metformin; Rats; T	2022
Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma. International journal of oncology, 2017, Volume: 50, Issue:6 Topics: Adenocarcinoma; Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Ga	2017
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017, Volume: 26, Issue:8 Topics: Adenocarcinoma; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors	2017
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. Toxicology in vitro : an international journal published in association with BIBRA, 2018, Volume: 47 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ca	2018
Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth. Cell death & disease, 2018, 02-07, Volume: 9, Issue:2 Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Apoptosis; Carcinogenesis; Carcinoma, Pancreatic Du	2018
Impact of metformin on gastric adenocarcinoma survival: A Belgian population based study. Cancer epidemiology, 2018, Volume: 53 Topics: Adenocarcinoma; Aged; Belgium; Cohort Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agent	2018
Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 113 Topics: Adenocarcinoma; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Dr	2019
Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. BJU international, 2019, Volume: 123 Suppl 5 Topics: Adenocarcinoma; Androgen Antagonists; Cell Survival; Diabetes Mellitus, Type 2; Humans; Hypoglycemic	2019
Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment. Molecular pharmaceutics, 2019, 07-01, Volume: 16, Issue:7 Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Hypoxia; Doxorubicin; Drug Compounding; Drug Deliver	2019
Diabetes and pancreatic cancer. JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4 Topics: Adenocarcinoma; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Panc	2013
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. International journal of oncology, 2013, Volume: 43, Issue:6 Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combine	2013
Metformin use and improved response to therapy in rectal cancer. Cancer medicine, 2013, Volume: 2, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Diabetes Mellitus, Type	2013
Metformin for castrate-resistant prostate cancer: learning more about an old dog's new tricks. European urology, 2014, Volume: 66, Issue:3 Topics: Adenocarcinoma; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms, Castration-Resist	2014
Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PloS one, 2014, Volume: 9, Issue:4 Topics: Adenocarcinoma; Blotting, Western; Cell Division; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assa	2014
Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. International journal of oncology, 2014, Volume: 45, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blot	2014
Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4 Topics: Adenocarcinoma; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Human	2014
Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PloS one, 2014, Volume: 9, Issue:12 Topics: Acetyl-CoA Carboxylase; Adenocarcinoma; AMP-Activated Protein Kinases; Animals; Berberine; Carcinoma	2014
Metformin use and the risk of esophageal cancer in Barrett esophagus. Southern medical journal, 2014, Volume: 107, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Barrett Esophagus; Case-Control Studies; Diabetes Me	2014
Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. International journal of oncology, 2015, Volume: 46, Issue:5 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferat	2015
Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice. Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:7 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Pro	2015
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer? European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb	2015
Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. Annals of surgical oncology, 2015, Volume: 22 Suppl 3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb	2015
Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus. Pancreas, 2016, Volume: 45, Issue:2 Topics: Adenocarcinoma; Age of Onset; Aged; Alcohol Drinking; Body Mass Index; Cohort Studies; Diabetes Mell	2016
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resis	2016
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. PloS one, 2015, Volume: 10, Issue:12 Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Epithelial	2015
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma. Current molecular medicine, 2016, Volume: 16, Issue:1 Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2	2016
Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointestinal endoscopy, 2016, Volume: 84, Issue:1 Topics: Adenocarcinoma; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Body	2016
Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells. Oncotarget, 2016, Apr-19, Volume: 7, Issue:16 Topics: Adenocarcinoma; Adult; AMP-Activated Protein Kinases; Apoptosis; Biomarkers, Tumor; Cell Movement; C	2016
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. International journal of oncology, 2016, Volume: 48, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell	2016
Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis. Oncotarget, 2016, Apr-26, Volume: 7, Issue:17 Topics: Adenocarcinoma; Apoptosis; Autophagy; Biomarkers, Tumor; CASP8 and FADD-Like Apoptosis Regulating Pr	2016
Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 06-01, Volume: 34, Issue:16 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Female; Humans; Male;	2016
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin. Oncotarget, 2016, Aug-30, Volume: 7, Issue:35 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia	2016
Metformin induces apoptosis of pancreatic cancer cells. World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47 Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C	2008
Metformin induces apoptosis of pancreatic cancer cells. World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47 Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C	2008
Metformin induces apoptosis of pancreatic cancer cells. World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47 Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C	2008
Metformin induces apoptosis of pancreatic cancer cells. World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47 Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C	2008
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:3 Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injur	2009
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 2009, Volume: 137, Issue:2 Topics: Adenocarcinoma; Age Distribution; Aged; Cancer Care Facilities; Case-Control Studies; Causality; Com	2009
Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell cycle (Georgetown, Tex.), 2010, Jan-01, Volume: 9, Issue:1 Topics: Adenocarcinoma; Age Factors; Animals; Female; Longevity; Male; Mammary Neoplasms, Animal; Melatonin;	2010
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro-oncology, 2011, Volume: 13, Issue:2 Topics: Active Transport, Cell Nucleus; Adenocarcinoma; AMP-Activated Protein Kinase Kinases; AMP-Activated	2011
Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma, 2011, Volume: 58, Issue:6 Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Humans; Hypoglycemic Agen	2011
Metformin inhibits the development and metastasis of ovarian cancer. Oncology reports, 2012, Volume: 28, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell	2012
Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Diabetes Complications; Diabetes	2013
Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bulletin of experimental biology and medicine, 2005, Volume: 139, Issue:6 Topics: Adenocarcinoma; Animals; Female; Homozygote; Hypoglycemic Agents; Longevity; Mammary Neoplasms, Anim	2005
Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology, 2001, Volume: 120, Issue:5 Topics: Adenocarcinoma; Animals; Cell Division; Cricetinae; Dietary Fats; DNA; Female; Glucose; Hypoglycemic	2001

metformin and Adenocarcinoma, Basal Cell